Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine

Psychopharmacology

Volumn 179, Issue 1, 2005, Pages 136-143

  Cho, Hyun Sang ^a,b,k   D'Souza, Deepak C ^a,b   Gueorguieva, Ralitza ^c,d   Perry, Edward B ^a,b   Madonick, Steven ^e   Karper, Laurence P ^f   Abi Dargham, Anissa ^g   Belger, Aysenil ^h   Abi Saab, Walid ^a,i   Lipschitz, Deborah ^a   Bennet, Alexandre ^j   Seibyl, John P ^a,b,c   Krystal, John H ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine   (United States)

^d YALE UNIVERSITY   (United States)

^e INSTITUTE OF LIVING   (United States)

^f Lehigh Valley Hosp and Hlth Netwk   (United States)

^g Columbia University ^*  (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^j Neuroscience Scientific Liaison   (United States)

^k Yonsei University   (South Korea)

more..

Author keywords

Glutamate; Ketamine; N methyl D aspartate (NMDA); Psychosis; Sensitization

Indexed keywords

KETAMINE;

ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG REEXPOSURE; DRUG SENSITIZATION; HUMAN; HUMAN CHARACTERISTIC; NORMAL HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; RATING SCALE; VISUAL ANALOG SCALE;

ADULT; BEHAVIOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 20944432145     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2066-5     Document Type: Article

References (78)

1. Abekawa T, Honda M, Ito K, Inoue T, Koyama T (2002) Effect of MS-153 on the development of behavioral sensitization to locomotion- and ataxia-inducing effects of phencyclidine. Psychopharmacology 160:122-131
2. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH (1998) The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31(Suppl 2):104-109
3. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998) Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43:811-816
4. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Cappiello A, Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57:270-276
5. Angrist BM, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology 72:17-19
6. Bell MD, Billington RJ, Becker BR (1985) Scale for the assessment of reality testing: reliability, validity, and factorial invariance. J Consult Clin Psychol 53:506-511
7. Benthuysen JL, Hance AJ, Quam DD, Winters WD (1989) Comparison of isomers of ketamine on catalepsy in the rat and electrical activity of the brain and behavior in the cat. Neuropharmacology 28:1003-1009
8. Berlant JL (1985) Reserpine and phencyclidine-associated psychosis: three case reports. J Clin Psychiatry 46:542-544
9. Black M, Lanthorn T, Small D, Mealing G, Lam V, Morley P (1996) Study of potency, kinetics of block and toxicity of NMDA receptor antagonists using fura-2. Eur J Pharmacol 317:377-381
10. Bowers MB, Heninger GR, Sternberg D, Meltzer HY (1980) Clinical processes and central dopaminergic activity in psychotic disorders. Commun Psychopharmacol 4:177-188
11. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11:125-136
12. Brown H, Prescott R (1999) Applied mixed models in medicine. Wiley, New York, NY
13. Byer DE, Gould AB (1981) Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology 54:225-256
14. Carpenter WT Jr (1999) The schizophrenia ketamine challenge study debate. Biol Psychiatry 46:1081-1091
15. Chapman LJ, Edell WS, Chapman JP (1980) Physical anhedonia, perceptual aberration, and psychosis proneness. Schizophr Bull 6:639-653
16. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC (1994): Putatively psychosis-prone subjects 10 years later. J Abnorm Psychology 103:171-183
17. Collier BB (1981) Long term dangers of ketamine anesthesia (letter). Br J Anaesth 53:552
18. Dalgarno P, Shewan D (1996) Illicit use of ketamine in Scotland. J Psychoact Drugs 28:191-199
19. Dillon P, Copeland J, Jansen K (2003) Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 69:23-28
20. D'Souza DC, Berman RM, Krystal JH, Charney DS (1999a) Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry 46:1060-1080
21. D'Souza DC, Gil R, Zuzarte E, Zimmerman L, Abi-Saab D, Damon D, White J, Krystal J (1999b) Glycine-ketamine interactions in healthy humans. Abstracts of the VIth International Congress on Schizophrenia Research, Santa Fe, New Mexico, USA. Schizophr Res 24(1-2):213
22. Fauman BJ, Fauman MA (1980) Chronic phencyclidine (PCP) abuse: a psychiatric perspective - Part II: Psychosis [proceedings]. Psychopharmacol Bull 16:72-73
23. Gessa GL, Pani L, Serra G, Fratta W (1995) Animal models of mania. Adv Biochem Psychopharmacol 49:43-66
24. Giannini AJ, Loiselle RH, Price WA, Giannini MC (1985) Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. J Clin Psychiatry 46:52-54
25. Greenberg BD, Segal DS (1985) Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol Biochem Behav 23:99-105
26. Haas DA, Harper DG (1992) Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 39:61-68
27. Hedlund JL, Vieweg BW (1980) The brief psychiatric rating scale (BPRS): a comprehensive review. J Oper Psych 11:48-64
28. Hocking G, Cousins MJ (2003) Ketamine in chronic pain management: an evidence-based review. Anesth Analg 97:1730-1739
29. Iwamoto ET (1986) Comparison of the pharmacologic effects of N-allylnormetazocine and phencyclidine: sensitization, cross-sensitization, and opioid antagonist activity. Psychopharmacology 89:221-229
30. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225
31. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277:953-955
32. Kalivas PW, Pierce RC, Cornish J, Sorg BA (1998) A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol 12:49-53
33. Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozapine Collaborative Study Group (1988) Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
34. Karper LP, Grillon C, Charney DS, Krystal J (1994) The effect of ketamine on prepulse inhibition and attention. Abstracts of the 33rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico
35. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
36. Klepstad P, Borchgrevink PC (1997) Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 41:422-426
37. Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS (1993) m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry. 50:624-635
38. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, neuroendocrine responses. Arch Gen Psychiatry 51:199-214
39. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS (1998a) Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135:213-229
40. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS (1998b) Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 55:354-360
41. Krystal JH, Abi-Dargham A, Laruelle M, Moghaddam B (1999a) Pharmacologic model psychoses. In: Charney DS, Nestler E, Bunney BS (eds) Neurobiology of mental illness. Oxford University Press, New York, pp 214-224
42. Krystal JH, D'Souza DC, Belger A, Cassello K, Madonick S, Sernyak M, Abi-Saab W (1999b) Amphetamine pretreatment reduces attention deficits, but not psychosis, produced by ketamine in healthy human subjects. Abstracts of the VIIth International Congress on Schizophrenia Research, Santa Fe, New Mexico, USA. Schizophr Res 36(1-3):309
43. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr, Vegso S, Heninger GR, Charney DS (1999c) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145:193-204
44. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S (1999d) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7:125-143
45. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (in press)
46. Lahti AC, Warfel D, Michaelidis T, Weiler MA, Frey K, Tamminga CA (2001) Long-term outcome of patients who receive ketamine during research. Biol Psychiatry 49:869-875
47. Laruelle M (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 31:371-384
48. Leccese AP, Marquis KL, Mattia A, Moreton JE (1986) The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats. Behav Brain Res. 22:257-264
49. Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205-229
50. Lipschitz DS, D'Souza DC, White JA, Charney DS, Krystal JH (1997) Clozapine blockade of ketamine effects in healthy subjects. Biol Psychiatry 41:238
51. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug - Sernyl. AMA Arch Neurol Psychiatry 81:363-369
52. MacLennen FM (1982) Ketamine tolerance and hallucinations in children (letter). Anaesthesia 37:1214-1225
53. Madonick S, D'Souza DC, Brush L, Cassello K, Sernyak M, Belger A, Krystal JH (1999) Assessment of glutamate-opiate interactions: a contribution to the pathophysiology of schizophrenia? Abstracts of the VIIth International Congress on Schizophrenia Research, Santa Fe, New Mexico, USA. Schizophr Res 36(1-3):310
54. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
55. Marshall RD, Garakani A (2002) Psychobiology of the acute stress response and its relationship to the psychobiology of post-traumatic stress disorder. Psychiatr Clin North Am 25:385-395
56. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey TS, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106-118
57. Oranje B, van Berkel BNM, Kemner C, van Ree JM, Kahn RS, Verbaten MN (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22:293-302
58. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812
59. Pal HR, Berry N, Kumar R, Ray R (2002) Ketamine dependence. Anaesth Intensive Care 30:382-384
60. Phillips M, Wang C, Johnson KM (2001) Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296:905-913
61. Reich DL, Silvay G (1989) Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 36:186-197
62. Robinson TE, Berridge KC (2001) Incentive-sensitization and addiction. Addiction 96:103-114
63. Rosen AM, Mukherjee S, Shinbach K (1984) The efficacy of ECT in phencyclidine-induced psychosis. J Clin Psychiatry 45:220-222
64. Rothman SM, Onley JW (1987) Excitotoxicity and the NMDA receptor. Trends Neurosci 10:299-302
65. Rothman RB, Gorelick DA, Baumann MH, Guo XY, Herning RI, Pickworth WB, Gendron TM, Koeppl B, Thomson LE III, Henningfield JE (1994) Lack of evidence for context-dependent cocaine-induced sensitization in humans: preliminary studies. Pharmacol Biochem Behav 49:583-588
66. Scalzo FM, Holson RR (1992) The ontogeny of behavioral sensitization to phencyclidine. Neurotoxicol Teratol 14:7-14
67. Spitzer RL, Williams JB, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R-Patient edition. American Psychiatric Press, New York, NY
68. Stefani MR, Moghaddam B (2002) Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res 134:267-274
69. Stewart J, Badiani A (1993) Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 4:289-312
70. Strakowski SM, Sax KW, Setters MJ, Stanton SP, Keck PE Jr (1997) Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry 42:749-755
71. Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM (2001) Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology 25:548-554
72. Thiemann S, Csernansky JG, Berger PA (1987) Rating scales in research: the case of negative symptoms. Psychiatry Res 20:47-55
73. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139-1147
74. White PF, Way WL, Trevor AJ (1982) Ketamine - its pharmacology and therapeutic uses. Anesthesiology 56:119-136
75. Willetts J, Balster RL, Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428
76. Wolf ME (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54:679-720
77. Wolf ME, Khansa MR (1991) Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res 562:164-168
78. Xu X, Domino EF (1994) Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav 47:603-608